Billions for the circular economyTogether with the EIB, five of the EUs largest national promotional banks and institutions plan to invest €10bn to accelerate the transition to a sustainable and circular economy. more ➔
Genmab launches US$502m IPODanish cancer antibody powerhouse Genmab plans to raise US$505m in its US IPO. The money will go towards its antibody therapeutics pipeline. more ➔
AM-Pharma raises €116m for Phase IIIDutch biopharma company AM-Pharma B.V. has secured €116m to bring its acute kidney injury treatment into Phase III. more ➔
US$5bn deal for GalapagosBelgian biotech Galapagos NV has entered into a R&D collaboration with Gilead Sciences. The US drug maker is paying up to US$5bn for Galapagos pipeline and drug discovery platform. more ➔
Boehringer snaps up cancer vaccine develop... German pharma major Boehringer Ingelheim has taken over Swiss cancer immunotherapy player AMAL Therapeutics. more ➔
€28.5m for microalgae expert MicrophytFrench microalgae specialist Microphyt has raised €28.5m to develop its microalgae portfolio for nutrition and cosmetics. more ➔
€8m for universal flu vaccine French biotech Osivax has raised €8m to fast-track development of its lead flu vaccine candidate – and branch out to Belgium. more ➔
BioNTech pulls in massive €290m financin...It is one of the largest single private funding rounds a biotech company in Europe has ever pulled off. German biotech BioNTech managed to raise US$325m (€290m) in an upsized Series B round to boost … more ➔
Biophytis launches €9m Nasdaq IPO Biophytis has priced its IPO on Nasdaq Paris. The company aims to raise up to €10.8m to advance its lead drug candidate under development for the treatment of neuromuscular diseases. more ➔
€30m for Evotec cancer spin-outGerman biotech group Evotec has once more launched a spin-off: Breakpoint Therapeutics GmbH is focusing on treating cancer patients by targeting DNA damage responses. more ➔
